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ABSTRACT
Malignant pleural mesothelioma (MPM), a rare malignancy with a poor prognosis, 
is mainly caused by exposure to asbestos or other organic fibers, but the underlying 
genetic mechanism is not fully understood. Genetic alterations and causes for 
multiple primary cancer development including MPM are unknown. We used whole 
exome sequencing to identify somatic mutations in a patient with MPM and two 
additional primary cancers who had no evidence of venous, arterial, lymphovascular, 
or perineural invasion indicating dissemination of a primary lung cancer to the pleura. 
We found that the MPM had R282W, a key TP53 mutation, and genome-wide allelic 
loss or loss of heterozygosity, a distinct genomic alteration not previously described 
in MPM. We identified frequent inactivating SETDB1 mutations in this patient and 
in 68 additional MPM patients (mutation frequency: 10%, 7/69) by targeted deep 
sequencing. Our observations suggest the possibility of a new genetic mechanism 
in the development of either MPM or multiple primary cancers. The frequent SETDB1 
inactivating mutations suggest there could be new diagnostic or therapeutic options 
for MPM.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is a 
rare malignancy with a highly unfavorable prognosis. 
Increased risk for MPM is strongly linked to exposure 
to asbestos or erionite [1–4]. Since asbestos had widely 
been used in different industries, the incidence of MPM 
in the United States is expected to steadily rise and peak 
over the next 20 years [1–4]. Clinical trials of single 
modality treatment with extrapleural pneumonectomy or 
pleurectomy, chemotherapy or radiation therapy have not 
significantly improved survival. Median survival ranges 
from 10–17 months [5–7].
The underlying genetic mechanisms of MPM 
development are not fully known. Molecular genetic 
analyses of MPMs have shown frequent deletions in 
chromosomes 1p, 3p, 4p, 4q, 6q, 9p, 13q, 14q, 15q, and 
22q [8–10]. Certain tumor suppressor genes located in 
these regions have been implicated, such as CDKN2A/
ARF at chromosome 9p21, NF2 at 22q12, and BAP1 
at 3p21, [4, 11–14], but for many of these regions, the 
driver genes remain to be identified. Since the first report 
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of transcriptome sequencing in MPM samples [15], 
large-scale genome analyses such as exome sequencing 
[16–18] and whole genome sequencing (WGS) [19–20] 
using MPM tissues or cultured cells identified potential 
molecular targets such as E2F1 [17], CUL1 [18], MET-
related pathway genes, and mSWI/SNF genes, the 
latter of which are important for histone modification 
and regulation [16]. These genetic alterations suggest 
potentially new therapeutic targets or diagnostic markers 
in addition to known frequent genetic alterations (NF2, 
CDKN2A, and BAP1) in MPM.
Interestingly, many genes involved in histone 
modification and regulation mechanisms undergo 
germline or somatic mutations [16]. SETDB1, a histone 
methyltransferase, is reportedly a potential oncogene 
in lung cancer [21]. A clinical trial for the SETDB1-
targeting drug mithramycin is underway for both lung 
cancer and mesothelioma (clinicaltrials.gov). A systematic 
analysis of SETDB1 and other genes involved in histone 
modification could help identify genetic mechanisms for 
MPM. Furthermore, although previous large-scale genome 
studies suggested potential drug targets and diagnostic 
markers for MPM, most studies were confined to focal 
changes of mutations such as small substitutions or 
insertions and deletions. A systemic large genomic change 
such as genome-wide deletion has not been reported 
for MPM.
It is uncommon to observe multiple primary tumors 
along with MPM in the same patient. There are few, if 
any, suggested genetic mechanisms for the development 
of multiple cancers in a patient who has MPM. Here, 
we present a rare case of a patient who had multiple 
primary cancers including MPM and suggest a potentially 
novel genetic mechanism that explains this unusual 
development. Targeted deep sequencing identified a 
frequently mutated gene, SETDB1, in this patient and 
several others with MPM.
RESULTS
Clinical characteristics of an MPM patient with 
two additional primary cancers
A 62-year-old Caucasian woman presented with 
persistent symptoms of fever, cough, chest pain and a left 
lower lobe consolidation on chest radiograph despite the 
use of antibiotics. Six months later, computed tomography 
of the chest revealed a discrete mass in the left lower lobe, 
which fine needle aspiration showed to be non-small cell 
lung cancer (Figure 1A). Positron emission tomography 
and a bone scan revealed no evidence of distant metastasis, 
and the patient was referred for a thoracic surgery 
evaluation. Her past medical history was significant for 
bladder cancer treated with transurethral bladder resection 
eight years earlier. She was a former smoker with a 30 
pack-year history and had worked for a construction 
company while in her forties with possible, but uncertain 
asbestos exposure.
Five months after her initial presentation, the patient 
underwent a left lower lobectomy with mediastinal lymph 
node dissection. On thoracotomy, scattered mass lesions 
were incidentally discovered on the pleural surface of 
the diaphragm and biopsied. Final pathology revealed 
a T1N0M0 lung adenocarcinoma in the left lower lobe 
and pleural biopsies indicated sarcomatoid pleural 
mesothelioma, which stained positive for calretinin 
(Figure 1B) and was staged as T3N0M0 because there 
was no evidence of venous, arterial, lymphovascular, 
or perineural invasion. Postoperatively, two cycles 
of neoadjuvant chemotherapy with carboplatin and 
pemetrexed resulted in some disease regression. The 
patient had a subsequent completion left pneumonectomy. 
She died from mesothelioma progression four months 
later.
Exome sequencing of the MPM patient’s tumor 
revealed a genome-wide allelic loss
The development of multiple primary malignancies 
including MPM led us to search for underlying genetic 
alterations in this patient. First, we performed whole 
exome sequencing on the mesothelioma and adjacent 
normal pleural tissue as a control. Among the 11 high-
confidence, non-synonymous variants identified, six 
were further validated by targeted deep or Sanger 
sequencing (Table 1). One key mutation identified was 
R282W in the TP53 tumor suppressor gene. R282W 
is a structural mutation that renders the DNA-binding 
domain of p53 unstable and is a common TP53 cancer-
related mutation [22–24], but has not been described in 
MPM. We also identified a nonsense mutation, Y249X, 
of SETDB1, a histone methyltransferase. SETDB1 is an 
oncogene frequently amplified in human lung cancers 
and melanomas [21, 25]. A frameshift mutation (V132fs) 
producing a premature stop codon in SETDB1 was also 
described in the ACCMESO1 mesothelioma cell line 
(Cancer Cell Line Encyclopedia (CCLE) database), 
which suggests a potential role of SETDB1 in MPM 
development.
Interestingly, most mutations identified in the 
MPM patient were highly enriched for the mutant allele, 
suggesting a homozygous alteration or deletion of wild-
type allele when minimal contamination of normal pleura 
in the MPM is considered (Figure 2A). Most variants 
identified showed a high frequency of mutant alleles, 
except variants on chromosomes 7 and 20 (Figure 2B). 
Analyses of allelic fraction between wild-type and variants 
in MPM tumor (Fig 3A, upper panel), as well as tumor 
allelic log ratio to normal (Fig 3A, lower panel) using all 
variants in exome sequencing, including known SNPs, 
revealed that this MPM showed genome-wide allelic 
loss or loss of heterozygosity (LOH). However, same 
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analyses showed a distinct pattern from another cancer 
that has many genetic alterations with focal allelic loss 
(Figure 3B). Although regional loss in chromosomes 1, 3, 
4, 6, 9, 10, 13, 14, 17 and 22 has been reported in MPMs 
[8–10], to the best of our knowledge, this type of extensive 
genome-wide allelic loss has not been described in MPM.
Further genetic analysis was not possible because 
the patient’s lung adenocarcinoma specimen was 
unavailable. Instead, we performed exome sequencing 
on a focus of atypical adenomatous hyperplasia (AAH), 
finding no evidence of the genome-wide allelic loss seen 
in MPM. However, a major driver mutation, G12C, in 
the KRAS oncogene, might have been involved in the 
development of this AAH. In our first targeted deep 
sequencing using the customized Ampliseq panel (Life 
Technologies) to validate mutation candidates from 
MPM, we sequenced six interesting candidates (KANK4, 
GBP4, SETDB1, ACTB, GOT1, and NOD2) in MPM. Four 
(SETDB1, ACTB, GOT1, and NOD2) were validated as 
true somatic mutations (Table 1).
Frequent inactivating mutations of SETDB1  
in MPM
Among the mutations validated by exome and 
targeted sequencing in MPM tumor samples, we found 
that SETDB1 had a nonsense mutation (Y249X). Because 
another inactivating frameshift mutation (V132fs) was 
reported in the mesothelioma cell line ACCMESO1, we 
analyzed mutations of SETDB1 for this whole coding 
Figure 1: Clinical diagnosis of lung adenocarcinoma and MPM. A. A 2 cm ground-glass opacity (arrow), later diagnosed as 
lung adenocarcinoma, was identified in the patient’s left lower lobe on chest CT scan. No pleural thickening or implants were noted on 
preoperative imaging. B. Immunohistochemical staining for calretinin confirmed the diagnosis of MPM (original magnification 20X).
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region by targeted deep sequencing of the whole coding 
exons of SETDB1 in 77 additional primary MPM tissues, 
for a total sample of 78 MPM tissues from 69 MPM 
patients. Up to 40,000X sequencing coverage was obtained 
from our custom-designed targeted sequencing panel. We 
identified seven somatic mutations from the 69 MPM 
patients; these mutations have not been reported in any 
other databases, including 1,000 genome, COSMIC, and 
dbSNP. Four point mutations and three deletions were 
identified from a total of six MPM patients (Table 2). 
Among these, two samples shared the same 17 bp deletion 
mutation (677_693del17) (Figure 4). All these somatic 
mutations were validated by three independent targeted 
sequencings with at least 500X coverage. Ten matched 
normal pleural samples were available from 69 
mesothelioma patients and sequenced to find any SETDB1 
variant, but none were identified. Finally, to determine 
whether SETDB1 mutation was correlated with overall 
survival of MPM patients, we divided 69 MPM patients 
based on SETDB1 mutation status. We found no significant 
correlation (p=0.351), probably because there were so few 
mutation-positive samples.
DISCUSSION
Our exome sequencing analysis of MPM in a 
patient who also had lung adenocarcinoma and a history 
of bladder cancer showed a rare case of MPM with 
genome-wide allelic loss. Although karyotyping to 
confirm genome-wide allelic loss would have been ideal, 
at the time the experiments were done, the patient had 
already died and no appropriate samples were available. 
We therefore used four different sequencing technologies 
(Exome, two targeted, and Sanger sequencing) and 
confirmed the genome-wide allelic loss.
Loss of p53 may lead tumor cells to be more 
vulnerable to unrepaired genomic instability in response 
to DNA damage or stress [22–24]. Chromothripsis 
involving massively rearranged chromosomal structure 
scattered with widespread genomic losses has been 
observed in several cancer genomes by analyzing their 
sequence fragments at the whole genome level [26–27]. 
Chromothripsis is strongly linked to TP53 germline 
or somatic mutations [26–27]. Although we could not 
clearly define or classify the genome-wide allelic loss 
phenomenon as a chromothripsis or similar event because 
of the limited number of variants identified in exome 
sequencing analysis, we could assume that bi-allelic 
inactivation of the TP53 tumor suppressor gene via 
R282W mutation and LOH played a critical role in the 
genomic abnormality observed in our MPM case. To the 
best of our knowledge, TP53 R282W mutation has not 
been reported in MPM patients. Because TP53 mutation is 
important for genomic instability such as chromothripsis, 
and R282W is a key mutation altering function of p53 [22-
24, 26-27], it would be meaningful to further examine the 
Table 1: Eleven high-confidencea non-synonymous variants identified by whole exomeb and targeted deep 
sequencingc
Gene Chromosome Protein change Nucleotide 
change




SETDB1 chr1 Y249X 747T>A nonsense 48 0.93 validated
DYSF chr2 R1604Q 4811G>A missense 111 0.83 not done
ATP2C1 chr3 W460R 1378T>A missense 99 0.86 not done
RAPGEF6 chr5 T325Sd 973A>T missense 51 0.85 validated
ACTB chr7 F262L 786C>G missense 37 0.35 validated
CASD1 chr7 V361L 1081G>T missense 39 0.62 not done
GOT1 chr10 T326I 977C>T missense 61 0.92 validated
GIT2 chr12 T28M 83C>T missense 43 0.88 not done
NOD2 chr16 Y240X 720T>A nonsense 39 0.92 validated
TP53 chr17 R282Wd 844C>T missense 37 0.96 validated
PSG1 chr19 E41Q 121G>C missense 42 0.84 not done
a High-confidence is defined by quality score (QSS) greater than 30.
b Whole exome sequencing was done on SOLiD 5500 (Life Technologies) using the TargetSeq Exome Enrichment kit (Life 
Technologies) as previously described. [32]
c Targeted deep sequencing for validation was done on Ion Torrent PGM using a customized AmpliSeq panel (Life 
Technologies) as previously described. [32] (Average coverage > 2000X).
d These mutations were confirmed by Sanger sequencing.
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relationship between TP53 R282W and a genome-wide 
loss in MPM. We believe this is the first report of genome-
wide allelic loss in a patient who developed multiple 
primary cancers including MPM. As genome-wide allelic 
loss can be easily overlooked by mutation-focused genetic 
analyses, our finding suggests that patients with multiple 
cancers including MPM may need to be screened for 
genome-wide allelic loss.
Another notable finding in this study was the high 
frequency of SETDB1 mutations in MPM. Exome and 
WGS studies have been done in MPM or peritoneal 
mesothelioma samples [16–20], but none reported 
SETDB1 as a new high frequent mutation in mesothelioma. 
We identified a somatic SETDB1 mutation by exome 
sequencing, validated it by targeted deep sequencing 
analysis, and sequenced 77 additional MPM samples 
using another targeted deep sequencing panel of SETDB1 
three times, which we believe clearly rules out a technical 
artifact of sequencing. There are several reasons that may 
explain why other studies did not find that SETDB1 was a 
frequent mutation in MPM, but we did. First, in previous 
studies, the SETDB1 gene was screened by exome or 
WGS in MPM [16–20]. Some studies used a targeted 
sequencing panel [28–29] that did not include the SETDB1 
gene. Exome or WGS approaches have around 10-100X 
coverage in general, which may miss a challenging mutant 
Figure 2: TP53 mutation and allele frequency of all variants. A. Sanger sequencing confirmed TP53 R282W mutation identified 
in exome and targeted deep sequencing of MPM. B. Allele frequency of variants identified in MPM with genome-wide allelic loss. 
Frequency of mutant alleles was higher (> 0.8) in most variants except for two located on chromosome 7.
Oncotarget8326www.impactjournals.com/oncotarget
Figure 3: Genome-wide allelic loss identified in a MPM patient with multiple primary cancers. A. Scatter plots show 
genome-wide allelic view of all variants including known SNPs identified in the patient’s MPM. Allelic fraction represents ratio of wild-
type to variant counts in an exome sequencing. B-allele fraction plot in the upper panel represents allelic ratio between wild-type and variant 
in the tumor sample. In the lower panel, the values (log2 ratio) of the x-axis are an allelic fraction of tumor normalized to that of matched 
normal pleura. The majority of variants on all chromosomes except chromosomes 7 and 20 show losses of either wild-type or variant allele 
in tumor. B. An example of genome-wide allelic view of tumor with frequent genetic alterations, but only with focal allelic loss. B-allele 
fraction plot of tumor sample in the upper panel and allelic fraction plot of tumor normalized to that of matched normal in the lower panel 
were newly generated from exome sequencing data previously reported [32].











777T Y249X 747T>A nonsense Loss of function 0.91
869T G869E 2606G>A missense damaging damaging Damaging 0.51
163T C911F 2732G>T missense damaging tolerated Uncertain 0.49
324T S947C 2840C>G missense benign damaging Uncertain 0.61
970T P226RfsX4 677_693del17 frameshift Loss of function 0.19
981T P226RfsX4 677_693del17 frameshift Loss of function 0.23
1278T F1250del 3747_3749del in-frame del Uncertain 0.14
bACCMESO1 V132EfsX3 395_399del5 frameshift Loss of function
cNYU695 K674SfsX73 2020delA frameshift Loss of function
a NM_001145415.1
b Previously reported mutation: ACCMESO1 - V132fs (CCLE, http://www.broadinstitute.org/ccle)




allele. In contrast, our coverage range of SETDB1 targeted 
deep sequencing was up to 40,000X—a difference that 
could explain why we detected the SETDB1 mutation. 
Second, previous studies analyzed single-digit sample 
sizes of MPM [16–20], except for one exome analysis 
[18] that included 22 MPM samples. Third, different 
types of samples were used for mutation screening, which 
may have affected the detection results. We used flash-
frozen tissues from MPM patients, whereas some previous 
studies [16–17] used cultured cells. Finally, we screened 
MPM samples, whereas some previous exome or WGS 
studies focused on peritoneal mesothelioma, another 
subtype [17,20].
SETDB1 has been reported to be amplified and 
a potential oncogene in lung cancer [21]. Increased 
expression of SETDB1 promotes tumor invasiveness and 
sensitizes anti-tumor growth by mithramycin, a SETDB1 
and Sp1 inhibitor [21]. Our finding that SETDB1 had a 
nonsense mutation (Y249X) and the fact that another 
inactivating frameshift mutation (V132fs) was reported 
in the mesothelioma cell line ACCMESO1, led us to 
hypothesize that truncating mutations such as nonsense 
and frameshift mutations are frequent in MPM. When we 
tested this using targeted deep sequencing analysis in 78 
MPM samples from 69 MPM patients, we found three 
deletion mutations. Two were the same 17 bp deletion 
mutations at exon 7 and the other was an in-frame deletion 
mutation (Table 2) (Figure 4). The remaining three 
mutations were novel missense mutations. Interestingly, 
while all predicted loss-of-function mutations except 
one are located in the N-terminal, missense and in-frame 
deletion mutations affecting single amino acid residues 
are located in the SET domain of SETDB1 (Figure 5) 
[30–31]. Although SETDB1 has been suggested to have 
an oncogenic impact in lung cancer based on transcription 
level or expression data [21,25], our results suggest that at 
Figure 5: Map of SETDB1 mutations identified in MPMs. Nine SETDB1 somatic mutations identified in this study and reported 
previously were mapped in domains of SETDB1. Four of five truncating mutations were located at the N-terminal (5’) regions before Tudor 
(Tud) domains. All three missense and one deletion mutation were found in the SET domain. Tud: Tudor; MBD: methyl-CpG-binding 
domain; pS: pre-SET; PS: post-SET [30–31].
Figure 4: Frequent SETDB1 mutations in MPM patients. Two types of deletion mutations from MPM patients, shown by 
an Integrative Genomics Viewer (IGV). A. 17 bp deletion (677_693del17) and B. In-frame deletion (3747_3749del) of SETDB1 were 
identified from different MPM patients.
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least some of the identified SETDB1 somatic mutations are 
probably loss of function mutations. Functional validation 
and characterization should be performed to prove 
this, but the different mutation spectrum suggests the 
location of somatic mutations on the SETDB1 functional 
domains may be important for oncogenic effect or tumor 
suppression. Exome sequencing in eight primary cultured 
cells from different subtypes of mesothelioma found that 
genes involved in histone modification and regulation 
mechanisms, such as BAP1, SETD2, USP49, and PRMT6, 
were mutated, suggesting somatic inactivation of histone 
modifier genes is important for mesothelioma development 
[16]. The same study also identified a truncating mutation 
of BAP1 and whole deletion of PRMT6 [16]. These 
results are consistent with our finding that mutations of 
SETDB1, histone methyltransferase, are frequent in MPM, 
suggesting that histone modifier genes, including SETDB1, 
are potentially important in MPM. Further functional 
studies are required to investigate a role of SETDB1 in 
MPM development.
In summary, we identified genome-wide allelic loss 
in a patient who had MPM and two additional primary 
cancers, results which suggest that careful analysis in 
exome sequencing is needed to detect genome-wide 
deletion in MPM samples with or without multiple primary 
cancers. The high frequency of mutations in SETDB1 that 
we found suggests that this and other histone-related genes 
are important in MPM.
MATERIALS AND METHODS
DNA extraction of 78 primary MPM tissues from 
69 MPM patients
DNA from a patient with multiple primary cancers 
(bladder, lung, and MPM), and 77 additional MPM 
tissues was extracted as described previously [32–33]. 
All samples were collected under a protocol (#11-06107) 
approved by the Committee for Human Research at the 
University of California, San Francisco. Clinical data for 
the 69 MPM patients is summarized in Supplementary 
Table 1.
Immunohistochemistry (IHC) staining
The MPM tissue slides from the patient with 
multiple primary cancers were used for IHC staining 
with anti-calretinin antibody (# 180211, ThermoFisher) 
as previously described [34]. Briefly, 5μm-thick slide 
sections were deparaffinized with xylene and steamed 
in citrate for 20 minutes. They were then treated with 
blocking solution, washed, and incubated overnight. The 
slides were washed again and incubated with solutions 
from the Invitrogen Histostain Plus Broad Spectrum Kit 
(85-9643), washed again, stained with hematoxylin for 1 
minute, mounted, and analyzed.
DNA library preparation and exome sequencing
Serial samples of normal tissue, atypical 
adenomatous hyperplasia (AAH), and MPM tissue from 
the patient with multiple cancers including MPM were 
used for the exome sequencing library preparation. 
SOLiD 5500 (Life Technologies) was used for whole 
exome sequencing according to the manufacturer’s 
protocol and our previous experiment [32]. Briefly, 3 ug 
of DNA was fragmented by Covaris S220 (Covaris), and 
the fragmented DNA was barcode ligated and amplified. 
After fragmented DNA was quantified, 500 ng of DNA 
was used for the TargetSeq Exome Enrichment kit (Life 
Technologies) to enrich the exome only. A diluted exome 
library was amplified by emulsion PCR and enriched. The 
prepared libraries were run onto the Flow Chip in SOLiD 
5500.
Targeted deep sequencing to validate somatic 
mutation candidates
To validate the identified mutations from the exome 
sequencing of the patient who had MPM and two other 
primary cancers, we designed a customized Ampliseq 
panel (Life Technologies) to sequence six mutation 
candidates (KANK4, GBP4, SETDB1, ACTB, GOT1, and 
NOD2). The Ion Ampliseq designer was used to make a 
targeted customized panel for these six genes according 
to the manufacturer’s protocol. Library preparation and 
sequencing were also done according to our previous 
protocol [32].
Targeted deep sequencing of SETDB1 in 78 
MPM tissues from 69 MPM patients
We designed another targeted panel of SETDB1 
covering all 21 coding exons spanning 6.05 kb (99.76% 
coverage) (CureSeq Inc, Brisbane, CA). A total of 31 
amplicons were designed and sequenced in 78 primary 
mesothelioma tissue samples. A library was prepared 
according to the manufacturer’s protocol (CureSeq 
Inc, Brisbane, CA). In brief, library preparation was 
performed on each sample with adaptor and barcode 
ligation. Sequencing adaptors and barcodes (CureSeq Inc, 
Brisbane, CA) for multiplex sequencing purposes were 
ligated to the amplicons using ligase. After purification, 
the library was quantified using the Agilent Bioanalyzer 
with High-Sensitivity DNA kits (Agilent Technologies) 
following the manufacturer’s protocol. Library emulsion 
and enrichment were performed using the Ion PGM One 
Touch 2 and Enrichment System machine according to the 
manufacturer’s protocol (Life Technologies). Library with 
Ion Sphere Particles (ISPs) was added to the reaction tube 
using Ion PGM Template reagents (Life Technologies). 
ISP emulsion and breaking were automated through the 
Ion PGM OneTouch 2 system. The recovered ISPs were 
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enriched by an Ion PGM ES machine using Dynabeads 
MyOne Streptavidin C1 beads (Life Technologies). 
Sequencing was done according to the manufacturer’s 
protocol with enriched ISPs using the 318 chips (Life 
Technologies) on an Ion Torrent PGM.
Analysis of exome and targeted sequencing data
Raw sequence data were converted to fastq format 
using BEDtools (version 2.17.0) to perform alignment 
to the human reference genome (hg19, NCBI Build 37) 
using the Burrows_Wheeler Aligner (BWA mem, version 
0.7.12). Aligned data were then grouped by sample data 
using picard (version 1.114). The Genome Analysis 
ToolKit (GATK version 3.3-0) was used to perform 
insertion and deletion realignment, base recalibration, 
and variant calling. Single nucleotide variants and 
insertions/deletions were detected by using GATK, and 
annotated afterwards with ANNOVAR [35]. Several 
databases were used for annotation filtering such as 
dbSNP and 1000 Genomes (www.1000genomes.org). All 
the annotated mutations were visualized by Integrative 
Genomics Viewer (IGV, version 2.3.43) to confirm. 
Python-based programs developed in-house were used to 
filter out common benign and recurrent artifact variants 
during the annotation validations with IGV. Mutation 
frequencies were calculated through the programs by 
using information obtained from processed bam files by 
comparing the reads containing the mutations and the 
total number of reads containing the region of mutations. 
Those samples which were validated for variants were 
reconfirmed through separate run process to rule out the 
experimental bias.
Sanger sequencing validation
Sanger sequencing as described previously [33] 
was done to validate TP53 R282W and RAPGEF6 T325S 
mutations in the sample from the MPM patient who had 
additional primary cancers.
Survival analysis of MPM patients according to 
SETDB1 mutation status
We divided 69 MPM patients into SETDB1 wild-
type (n=62) and mutant (n=7) groups. Overall survival 
rates were determined using the Kaplan-Meier method in 
SPSS V22.0 for Mac. Survival rates were compared using 
the log-rank test. Two-sided P values less than 0.05 were 
considered statistically significant.
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